1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More

[Pelican Press 0]

This is the hidden content, please

• Sign In
• or
• Sign Up

1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More

If you’re willing to be patient, biotech stocks can offer significant upside, even if you only invest a relatively small amount, like $1,000. In that vein, Madrigal Pharmaceuticals (NASDAQ: MDGL) has a lot to offer. Between its recently launched new ***** and being the first in its market, it has a long runway for growth. Here’s why it’s worth an investment today, provided that you’re willing to hold on to your shares for at least a few years.

Madrigal makes a medicine called Rezdiffra, which is currently the only approved treatment for metabolic-associated steatohepatitis (MASH, formerly known as NASH) in patients with moderate to advanced fibrosis (scarring) of the liver. Right now, its

This is the hidden content, please

• Sign In
• or
• Sign Up

comprises the roughly 315,000 patients in the U.S. with MASH who are already diagnosed and in the care of specialists, but its

This is the hidden content, please

• Sign In
• or
• Sign Up

could one day be as large as the entire population of 1.5 million people in the U.S. who have some form of MASH.

Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day. 

This is the hidden content, please

• Sign In
• or
• Sign Up

Since its approval in mid-March of 2024, sales of Rezdiffra are increasing expediciously, reaching $62.2 million in Q3, the *****’s first full quarter on the market. A mere year ago, Madrigal had no revenue at all, and it’s likely that its revenue will continue to rise for at least a couple of years as its commercial rollout continues.

Right now, more than 6,800 patients are taking the treatment. The company hopes to get the ***** approved for ***** in the E.U. sometime in the second half of 2025, which will be a major catalyst for further growth.

The next hurdle to clear is for it to become profitable as its growth accelerates. In the third quarter, its operating expenses were $178.5 million, and it reported cash, equivalents, restricted cash, and short-term investments worth $1 billion. In other words, it has plenty of time to reach profitability before it would need to raise additional capital. And that’s a solid set of reasons to consider investing $1,000 in the stock.

Madrigal probably won’t be the only competitor in the market for MASH drugs forever. But one of the most powerful aspiring entrants, Novo Nordisk, may not be as intimidating for the biotech as it once was. Novo’s molecule semaglutide (commonly known by the trade names Ozempic and Wegovy) is already marketed to treat cardiometabolic illnesses like type 2 diabetes and obesity, both of which are illnesses commonly present in patients with MASH.

Story Continues

Per the recently published results of a phase 3 clinical trial investigating semaglutide’s helpfulness in treating MASH, its efficacy is fairly similar to that of Rezdiffra, albeit likely slightly better. But as Madrigal’s management is quick to point out, semaglutide is not something that patients find easy to take, so Rezdiffra may have an edge in tolerability over the long term.

Novo will take a bit longer in getting its therapy approved to treat MASH, and even longer to get approval for key expanded indications like cirrhosis with MASH that Madrigal could potentially get relatively soon. So there are no signs that semaglutide will devour so much market share as to slow Rezdiffra’s growth in any meaningful way, at least for now.

Nor is it guaranteed that other aspiring competitors like Eli Lilly will fare significantly better. If anything, it looks like Madrigal will be able to find a home in the market even when it’s among giants.

Therefore, it is very likely that as it continues to penetrate its market, this biotech stock will continue to post a fast rate of growth. And that’s another reason to buy its stock and hold it for the next five years or more.

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a

This is the hidden content, please

• Sign In
• or
• Sign Up

recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

This is the hidden content, please

• Sign In
• or
• Sign Up

: if you invested $1,000 when we doubled down in 2010, you’d have $23,446!*

Apple: if you invested $1,000 when we doubled down in 2008, you’d have $42,982!*

This is the hidden content, please

• Sign In
• or
• Sign Up

: if you invested $1,000 when we doubled down in 2004, you’d have $428,758!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

This is the hidden content, please

• Sign In
• or
• Sign Up

*Stock Advisor returns as of November 4, 2024

This is the hidden content, please

• Sign In
• or
• Sign Up

has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a

This is the hidden content, please

• Sign In
• or
• Sign Up

.

This is the hidden content, please

• Sign In
• or
• Sign Up

was originally published by The Motley Fool

This is the hidden content, please

• Sign In
• or
• Sign Up

#Growing #Biotech #Stock #Buy #Today #Hold #Years

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up